Source: Abzena & reported by http://pipelinereview.com/
CAMBRIDGE, UK and DIEPENBEEK, Belgium I May 19, 2015 I Abzena plc (AIM:ABZA), a life sciences company providing services and technologies that enable the development of biopharmaceutical products, announced today that its subsidiary Antitope Limited has entered into an agreement with Apitope, a private European biotech company focused on the discovery and development of disease-modifying treatments for autoimmune diseases. Under the agreement, Antitope will investigate and measure the immunological status of haemophilia A patients after treatment.
Apitope’s patented discovery platform enables selection of potential disease-modifying peptide therapies for the autoimmune disease of interest. It has a pipeline of compounds in development including ATX-F8-117, which has been designed to induce immune tolerance to blood coagulation factor VIII in haemophilia A patients.
Haemophilia A is caused by a deficiency in blood coagulation factor VIII and is treated with replacement factor VIII protein. About 30% of haemophilia A patients develop neutralising antibodies to factor VIII which inhibits its activity and thus renders treatment less effective. Such patients are at risk of serious and life-threatening bleeding.
Read more: http://pipelinereview.com/index.php/2015051957752/More-News/Abzena-to-provide-Apitope-with-Analytical-Support-for-Development-of-a-Novel-Treatment-for-Factor-VIII-Inhibitors-in-Haemophilia-A-Patients.html